ResMed Acquires Noctrix Health for $340m to Expand Beyond Sleep Apnoea

nuaxia
4 days ago
4 min read

ResMed has completed its $340m acquisition of Noctrix Health, adding a newly approved neurostimulation therapy for restless leg syndrome (RLS) to its growing sleep medicine portfolio.

The deal brings Noctrix’s flagship product, Nidra, into ResMed’s ecosystem and signals a broader shift in sleep medicine: expanding beyond respiratory disorders into adjacent neurological and sleep-related conditions that affect millions of patients worldwide.

For ResMed, the acquisition represents an opportunity to deepen its presence across the sleep care continuum while diversifying beyond its traditional strength in sleep apnoea treatment.

Adding a New Category to Sleep Medicine

Noctrix’s lead product, Nidra, is a non-pharmacological therapy designed for patients with restless leg syndrome who have not responded adequately to medication.

The system consists of wearable cuffs positioned below the knee that deliver mild electrical stimulation to the peroneal nerves.

This approach, known as tonic motor activation (TOMAC), activates neural pathways associated with voluntary movement, helping to reduce the uncomfortable sensations and involuntary muscle activity commonly experienced by patients with RLS.

Unlike traditional pharmaceutical treatments, Nidra aims to address symptoms without introducing additional drug burden, an increasingly attractive proposition as healthcare systems look to reduce long-term medication dependency.

The therapy received de novo clearance from the US Food and Drug Administration in 2023, establishing a new regulatory category for the treatment.

A Large and Underserved Patient Population

Restless leg syndrome remains one of the most common sleep-related neurological disorders.

Research from the American Academy of Sleep Medicine suggests that approximately 13% of Americans report having been diagnosed with the condition.

Despite its prevalence, treatment options remain relatively limited, particularly for patients who fail to respond to existing pharmaceutical therapies or experience undesirable side effects.

The acquisition gives ResMed access to a sizeable patient population that overlaps significantly with its existing sleep-focused customer base.

This creates potential opportunities for integrated diagnosis, treatment, and patient management across multiple sleep disorders.

Building a Broader Sleep Health Platform

ResMed has historically been best known for its leadership in sleep apnoea treatment through products such as the AirSense continuous positive airway pressure (CPAP) platform.

The company also maintains a significant respiratory care business through products including the Astral and Stellar ventilator systems.

Adding Nidra extends ResMed’s portfolio into neurostimulation-based sleep therapies and reflects a wider industry trend towards building comprehensive disease ecosystems rather than focusing on individual products.

Rather than competing solely within the sleep apnoea market, ResMed is increasingly positioning itself as a broader sleep health company capable of addressing multiple conditions that impact sleep quality and long-term patient outcomes.

A Milestone Exit for Angelini Ventures

The acquisition also represents the first successful exit for Angelini Ventures, the corporate venture capital arm of Angelini Industries.

Launched in 2022 with an initial €300m investment commitment, the fund focuses on biotechnology, medtech, and digital health companies addressing significant unmet medical needs.

Angelini participated in Noctrix's $40m Series C financing round in 2022, supporting the company through the final stages of clinical development and commercialisation.

The transaction provides an early validation of the fund’s investment strategy and demonstrates continued investor appetite for differentiated medical device companies with strong clinical evidence and regulatory approval.

Why This Deal Matters Now

The ResMed–Noctrix acquisition highlights several important trends across healthcare and medtech:

Non-pharmacological therapies are gaining traction as alternatives to chronic drug treatment.
Neurostimulation technologies are expanding beyond traditional neurological applications into sleep medicine.
Sleep health is evolving into a broader therapeutic category encompassing multiple disorders.
Medtech companies are increasingly acquiring adjacent technologies to create integrated patient ecosystems.
Investors continue to reward clinically validated devices that address large unmet patient populations.

The transaction also reflects growing recognition that sleep disorders rarely exist in isolation, creating opportunities for companies that can offer comprehensive solutions across diagnosis, treatment, and ongoing patient management.

What This Means for the Industry

The acquisition signals an important shift in how sleep medicine is developing.

Historically dominated by respiratory therapies and pharmaceuticals, the market is increasingly incorporating wearable technologies, neurostimulation devices, and digital health solutions.

As healthcare providers seek more personalised and less invasive treatment approaches, therapies such as TOMAC may become an increasingly important part of the sleep medicine toolkit.

For ResMed, the acquisition expands both its addressable market and its ability to support patients across a wider range of sleep-related conditions.

Summary

ResMed’s $340m acquisition of Noctrix Health brings FDA-authorised TOMAC therapy for restless leg syndrome into one of the world's largest sleep medicine platforms.

Beyond adding a single product, the deal reflects a broader evolution in sleep healthcare, where companies are moving beyond individual disorders to build integrated ecosystems capable of treating multiple conditions that affect sleep quality and patient wellbeing.

As non-drug therapies continue to gain momentum, the acquisition positions ResMed to play a larger role in the future of comprehensive sleep health management.

Discover how nuaxia can support your next medical education initiative: